pI: 10.3707 |
Length (AA): 597 |
MW (Da): 65757 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 1
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 8 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
205 | 418 | 2jbw (A) | 90 | 287 | 14.00 | 0 | 1 | 0.313859 | 0.32 |
236 | 345 | 2oxe (A) | 79 | 183 | 22.00 | 0 | 1 | 0.277655 | 0.34 |
237 | 416 | 3og9 (A) | 6 | 179 | 11.00 | 0 | 0.22 | 0.320908 | -0.05 |
241 | 596 | 3bf7 (A) | 13 | 254 | 31.00 | 0 | 1 | 0.417715 | 0.86 |
244 | 369 | 3p2m (A) | 81 | 181 | 40.00 | 0.055 | 0.9 | 0.353355 | 0.99 |
538 | 596 | 1brt (A) | 219 | 277 | 39.00 | 0.71 | 0.18 | 0.395127 | 0.03 |
538 | 597 | 1imj (A) | 153 | 209 | 23.00 | 0 | 0.15 | 0.288903 | -0.19 |
540 | 594 | 4ccw (A) | 238 | 292 | 29.00 | 0 | 0.13 | 0.419527 | -0.47 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | VEG Tachyzoite. | Gregory |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | ME49 Tachyzoite, ME49 merozoite, ME49 Bradyzoite. | Gregory Hehl AB Sibley/Greg |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 0-20% percentile | ME49 Oocyst. | Fritz HM |
Hehl AB | Asexual expansion of Toxoplasma gondii merozoites is distinct from tachyzoites and entails expression of non-overlapping gene families to attach, invade, and replicate within feline enterocytes. |
Sibley/Greg | ToxoDB |
Fritz HM | Transcriptomic analysis of toxoplasma development reveals many novel functions and structures specific to sporozoites and oocysts. |
Gregory | ToxoDB |
Ortholog group members (OG5_128173)
Species | Accession | Gene Product |
---|---|---|
Brugia malayi | Bm1_49325 | hydrolase, alpha/beta fold family protein |
Candida albicans | CaO19.13246 | match to pfam alpha/beta hydrolase fold |
Candida albicans | CaO19.2352 | similar to S. cerevisiae YGR031W |
Candida albicans | CaO19.5824 | match to pfam alpha/beta hydrolase fold |
Candida albicans | CaO19.9888 | similar to S. cerevisiae YGR031W |
Caenorhabditis elegans | CELE_R05D7.4 | Protein R05D7.4 |
Dictyostelium discoideum | DDB_G0278415 | hypothetical protein |
Drosophila melanogaster | Dmel_CG2059 | CG2059 gene product from transcript CG2059-RB |
Drosophila melanogaster | Dmel_CG14717 | CG14717 gene product from transcript CG14717-RB |
Escherichia coli | b0686 | acyl-CoA esterase |
Echinococcus granulosus | EgrG_000708700 | abhydrolase domain containing protein 11 |
Echinococcus multilocularis | EmuJ_000708700 | abhydrolase domain containing protein 11 |
Homo sapiens | ENSG00000106077 | abhydrolase domain containing 11 |
Leishmania braziliensis | LbrM.13.0940 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_131040.1 | Alpha/beta hydrolase family, putative |
Leishmania infantum | LinJ.13.1040 | hypothetical protein, conserved |
Leishmania major | LmjF.13.1140 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.13.1140 | hypothetical protein, conserved |
Loa Loa (eye worm) | LOAG_00082 | hypothetical protein |
Mus musculus | ENSMUSG00000040532 | abhydrolase domain containing 11 |
Mycobacterium tuberculosis | Rv0045c | Possible hydrolase |
Mycobacterium ulcerans | MUL_0063 | hydrolase |
Neospora caninum | NCLIV_016980 | hydrolase, alpha/beta fold family domain- containing protein, putative |
Plasmodium berghei | PBANKA_0906000 | alpha/beta hydrolase, putative |
Plasmodium falciparum | PF3D7_1143000 | alpha/beta hydrolase, putative |
Plasmodium knowlesi | PKNH_0940900 | alpha/beta hydrolase, putative |
Plasmodium vivax | PVX_092755 | alpha/beta hydrolase, putative |
Plasmodium yoelii | PY04076 | putative esterase/lipase hi0193 |
Saccharomyces cerevisiae | YGR031W | Imo32p |
Schistosoma japonicum | Sjp_0217850 | ko:K01175 ABHD11,abhydrolase domain containing 11 [EC:3.1.-.-], putative |
Schistosoma mansoni | Smp_193750 | family S33 non-peptidase homologue (S33 family) |
Schmidtea mediterranea | mk4.000999.02 | Family S33 non-peptidase homologue |
Trypanosoma brucei gambiense | Tbg972.11.4220 | hypothetical protein, conserved |
Trypanosoma brucei | Tb927.11.3690 | Alpha/beta hydrolase family, putative |
Trypanosoma congolense | TcIL3000.11.3640 | Alpha/beta hydrolase family, putative |
Trypanosoma cruzi | TcCLB.509683.40 | Alpha/beta hydrolase family, putative |
Trypanosoma cruzi | TcCLB.508731.20 | Alpha/beta hydrolase family, putative |
Toxoplasma gondii | TGME49_240830 | hydrolase, alpha/beta fold family protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb11.02.1170 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb11.02.1170 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb11.02.1170 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb11.02.1170 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
b0686 | Escherichia coli | non-essential | goodall |
PBANKA_0906000 | Plasmodium berghei | Dispensable | plasmo |
TGME49_240830 this record | Toxoplasma gondii | Probably essential | sidik |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Mus musculus | abhydrolase domain containing 11 | Compounds | References |
Homo sapiens | abhydrolase domain containing 11 | Compounds | References |